Moleculin announces US Phase 1 AML trial completion for Annamycin
Category: #health  By Mateen Dalal  Date: 2020-02-05
  • share
  • Twitter
  • Facebook
  • LinkedIn

Moleculin announces US Phase 1 AML trial completion for Annamycin

Moleculin Biotech, Inc., a preclinical pharmaceutical company and developer of anti-cancer drug candidates, has recently announced the completion of its US Phase 1 trial. The open label, single arm clinical trial met its primary objective to examine the safety of Annamycin (Liposomal Annamycin) for treating relapsed or refractory AML (acute myeloid leukemia).

Moleculin is testing Annamycin in Europe and the U.S. Interim enrollment, safety and potential efficacy data in a parallel Phase 1 trial held in Europe has also been updated. The study continued with dose escalation, with result showing no indication of safety concerns.

11 patients in Europe were dosed at various levels, which range from 120 mg/m² - 210 mg/ m². Out of these, two AML patients are currently receiving 210 mg/ m² single dose, having been enrolled in the 4th cohort in Europe. As per combined records of the U.S. and Europe trials, out of 14 patients who were evaluated and received Annamycin at or above 120 mg/m², 9 patients were considered relapsed while 5 patients were considered refractory.

The primary endpoint of the trial was met, after results showed the safety of this anthracycline antibiotic in treating AML patients, when delivered at or below the FDA-mandated lifetime maximum dose. The investigation showed positive signals owing to the absence of potential cardiotoxicity occurrence in any of the six patients evaluated. This safety signal was determined by indicators like echocardiograms and cardiac health biomarkers.

In the preliminary trial, CR (complete response), PR (partial response), overall survival (Kaplan-Meier), event-free survival, and duration of response/remission were recorded. Despite the drug being administered at only sub-therapeutic levels, 2 US patients showed efficacy in this initial trial.

As per Walter Klemp, Chairman and CEO of Moleculin, the positive result obtained under this trial is highly significant as it cleared the doubts of clinical advisors who question the effectiveness of single agents in AML patients. In order to address yet unmet medical needs, the company will seek approval from the FDA and expedite access to the Annamycin antibiotic, if it proves effective in many patients.

Source credit:

https://ir.moleculin.com/press-releases/detail/150/moleculin-announces-successful-completion-of-us-phase-1-aml

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Alphabet’s Google to face lawsuit from NLRB for violating labor laws
Alphabet’s Google to face lawsuit from NLRB for violating labor laws
By Mateen Dalal

In a recent turn of events, U.S. government body National Labor Relations Board (NLRB) has reportedly issued a complaint against American multinational technology company, Google LLC for unlawfully monitoring as well as questioning its workers and su...

Britain’s CMA to levy tougher competition rules on Google and Facebook
Britain’s CMA to levy tougher competition rules on Google and Facebook
By Mateen Dalal

Facebook and Google accounted for around 80% of the total 14 billion pounds spent on digital advertising in 2019. MOW has reportedly accused Google of modifying its Chromium developer tools and Chrome browser to get greater control over advertiser...

Amazon, U.S. Government team up to prevent sale of counterfeit goods
Amazon, U.S. Government team up to prevent sale of counterfeit goods
By Mateen Dalal

According to reliable sources, Washington-headquartered American multinational technology company, Amazon.com Inc has reportedly initiated a joint venture with the U.S. government’s counterfeit agency, the IPR Center (National Intellectual Prop...